49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-121864
01/6/2012A Phase I study of rontalizumabA Phase I study of rontalizumab Systemic lupus erythematosus (SLE)Intervention name : Rontalizumab
Dosage And administration of the intervention : Single and multiple subcutaneous administration of 3 different doses of rontalizumab
Control intervention name : null
Chugai Pharmaceutical Co., Ltd.NULL2064BOTH21Phase 1NULL
2NCT00962832
(ClinicalTrials.gov)
September 200919/8/2009A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus ErythematosusA Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: Placebo;Drug: RontalizumabGenentech, Inc.NULLCompleted18 Years65 YearsBoth238Phase 2United States;Argentina;Colombia;Mexico;Poland;Russian Federation;United Kingdom